^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Inlyta (axitinib) (VEGFR inhibitor) + Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia
Published date:
11/02/2023
Excerpt:
In the dose-response matrix analysis (Fig. 1C), AXI treatment alone at 100 nM inhibited the growth of the K562/T315 mut cell line by 38.42%, and ASC treatment alone at 100 nM, by 36.52%. Of note, the combination of AXI at 25nM and ASC at 12.5nM inhibited cell growth by 38.1%, and the combination of AXI at 12.5nM and ASC at 25nM showed 38.42% inhibition, which is similar to the inhibition achieved by 100nM of each drug alone.
DOI:
https://doi.org/10.1182/blood-2023-185440
